Results 281 to 290 of about 349,940 (358)

Combined Biologics and Exclusive Enteral Nutrition Promote Early Transmural Healing and Improve Long‐Term Outcomes in Crohn's Disease: A Multicenter Retrospective Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Study design and flow chart. From October 2016 to 2024, we searched the Crohn’s disease (CD) patient databases of three IBD centers in Hubei Province and identified 598 CD patients. Among them, 179 were in clinical remission and 38 had mild disease and were therefore excluded based on the study criteria.
Haixia Ren   +16 more
wiley   +1 more source

Pharmacomicrobiomics

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Oral medications encounter gut commensal microbes that participate directly and indirectly in drug effects through metabolism, interactions with drug metabolites, or production of substrates that compete with drugs for drug‐metabolizing enzymes, consequently influencing drug pharmacokinetics.
Naomi Gronich   +11 more
wiley   +1 more source

Biodistribution of nanoplastics in mice: advancing analytical techniques using metal-doped plastics. [PDF]

open access: yesCommun Biol
Staufer T   +10 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy